Retrospective IS phase | Prospective IIM phases | ||||
---|---|---|---|---|---|
0–3 months | 0–3 months | 3–6 months | 6–9 months | 9–12 months | |
IV iron treatment | n = 195 | n = 195 | n = 171 | n = 156 | n = 151 |
Number of IV iron doses per patient | |||||
Mean (SD) | 5.4 (3.0) | 5.6 (3.1) | 5.1 (2.8) | 5.0 (2.7) | 5.2 (3.0) |
p-valuea | 0.4664 | 0.3533 | 0.2313 | 0.5874 | |
Cumulative IV iron dose (mg) per patient | |||||
Mean (SD) | 534.4 (296.7) | 561.0 (305.8) | 515.2 (283.1) | 503.2 (267.2) | 528.5 (301.2) |
Mean (SD) monthly | 178.1 (98.9) | 187.0 (101.9) | 171.7 (94.4) | 167.7 (89.1) | 176.2 (100.4) |
p-valuea | 0.3071 | 0.5650 | 0.3530 | 0.8036 | |
ESA treatment | n = 195 | n = 195 | n = 171 | n = 156 | n = 151 |
Patients with ESA, n (%) | 175 (89.7) | 163 (83.6) | 153 (89.5) | 143 (91.7) | 140 (92.7) |
Number of ESA doses per patient | |||||
Mean (SD) | 19.4 (11.1) | 17.5 (11.7) | 20.1 (12.3) | 18.6 (11.3) | 20.1 (12.5) |
Median (IQR)b | 14.0 (12.0–26.0) | 14.0 (8.0–25.0) | 17.0 (10.0–29.0) | 15.0 (9.0–26.0) | 16.0 (9.0–32.0) |
p-valuea | 0.0468 | 0.9228 | 0.2840 | 0.8250 | |
Cumulative ESA dose (1000 IU) weekly per patient | |||||
Mean (SD) | 8.0 (8.1) | 7.4 (6.5) | 8.7 (8.0) | 9.0 (9.3) | 8.9 (7.4) |
Median (IQR)b | 6.0 (3.3–10.7) | 5.7 (2.7–10.0) | 6.7 (2.9–12.0) | 6.0 (3.0–10.8) | 7.0 (3.0–11.0) |
p-valuea | 0.4131 | 0.5745 | 0.8107 | 0.3248 |